Robot-Assisted Percutaneous Coronary Intervention (PCI) Market Report 2025

The robot-assisted percutaneous coronary intervention (PCI) market size has grown exponentially in recent years. It will grow from $19.59 billion in 2024 to $27.56 billion in 2025 at a compound annual growth rate (CAGR) of 40.7%. The growth in the historic period can be attributed to the increasing number of clinical trials supporting robotic percutaneous coronary intervention, higher procedural success rates compared to conventional PCI, expansion of physician training programs for robotic systems, rising patient preference for advanced treatment options, and broader availability of reimbursement policies in developed regions.

The robot-assisted percutaneous coronary intervention (PCI) market size is expected to see exponential growth in the next few years. It will grow to $106.86 billion in 2029 at a compound annual growth rate (CAGR) of 40.3%. The growth in the forecast period can be attributed to the increasing integration of 5G and real-time remote operation capabilities, expansion of robotic percutaneous coronary intervention systems into ambulatory surgical centers, heightened focus on reducing hospital stays post-PCI, rising venture capital interest in robotic cardiology startups, and growing incorporation of machine learning for procedural planning and guidance. Major trends in the forecast period include development of cloud-based robotic PCI platforms for real-time data sharing, implementation of advanced cybersecurity measures to protect robotic procedural data, creation of robotic systems optimized for outpatient cardiac care, innovation in AI-powered robotic learning from procedural datasets, and advancement of miniaturized robotic tools for ultra-precise coronary navigation.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the robot-assisted percutaneous coronary intervention (PCI) market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart attacks, and strokes. This increase is primarily attributed to sedentary lifestyles, resulting in obesity, hypertension, and poor heart health. Robot-assisted percutaneous coronary intervention (PCI) addresses these conditions by precisely reopening blocked or narrowed coronary arteries to restore blood flow to the heart while minimizing procedural risks and radiation exposure, thereby improving patient outcomes. For example, according to the American Heart Association, in January 2024, there were 131,454 deaths in the U.S. primarily linked to high blood pressure in 2022, up from 124,508 deaths in 2021. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the robot-assisted PCI market.

Leading companies in the robot-assisted percutaneous coronary intervention (PCI) market are investing in advanced robotic cardiology platforms to enhance patient safety and simplify complex coronary procedures. A robotic cardiology platform is a sophisticated system that assists cardiologists in performing precise and controlled coronary interventions while improving accuracy, reducing human error, and minimizing radiation exposure for both patients and medical personnel. For instance, in May 2023, Robocath SAS, a France-based firm specializing in robotic vascular intervention solutions, launched the R-One+. This cutting-edge robotic system allows interventional cardiologists to perform coronary angioplasties (PCI) by operating devices via an integrated command unit in the catheterization lab or control room. The R-One+ boosts precision in device handling, enhances safety for patients and staff by lowering radiation exposure, and provides more comfortable working conditions for operators. Its unveiling at the EuroPCR conference in Paris highlighted new capabilities that make PCI procedures safer and more efficient while protecting the cardiology team from radiation-related injuries. This launch underscores Robocath's dedication to advancing cardiovascular disease treatment through intelligent robotic assistance.

In July 2022, Medtronic Plc, an Ireland-based company offering robotic-assisted surgical devices, partnered with CathWorks to transform coronary care through AI-driven, non-invasive diagnostics. The collaboration seeks to improve the diagnosis and treatment of coronary artery disease using CathWorks' AI-based FFRangio system, enabling faster, more reliable, and non-invasive clinical decision-making. CathWorks, an Israel-based company, provides an artificial intelligence-enabled platform designed to revolutionize cardiovascular disease diagnosis and management.

Major players in the robot-assisted percutaneous coronary intervention (pci) market are Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Intuitive Surgical, BIOTRONIK SE & Co. KG, MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Group Holdings Limited, Medical Microinstruments, Quantum Surgical, Stereotaxis Inc., THINK Surgical Inc., Perfint Healthcare, Robocath Inc., SS Innovations, Auris Health, EP Solutions SA, NDR Medical Technology, Meril Life Sciences Pvt. Ltd.

North America was the largest region in the robot-assisted percutaneous coronary intervention (PCI) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in robot-assisted percutaneous coronary intervention (PCI) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the robot-assisted percutaneous coronary intervention (PCI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Robot-assisted percutaneous coronary intervention (R-PCI) is a minimally invasive procedure in which robotic systems help navigate catheters, balloons, and stents to treat narrowed or blocked coronary arteries. This technology enhances precision, stability, and control, reducing human error while also minimizing radiation exposure for both patients and healthcare staff. The approach aims to improve procedural safety, efficiency, and overall clinical outcomes.

The primary components of robot-assisted PCI include robotic systems, catheters and guidewires, and control consoles. Robotic systems are advanced machines that enable physicians to remotely manipulate guidewires, balloons, and stents from a protected workstation. R-PCI is utilized in procedures such as coronary angioplasty, stent placement, and thrombectomy, and serves end users including hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and other healthcare facilities.

The robot-assisted percutaneous coronary intervention (PCI) market research report is one of a series of new reports that provides robot-assisted percutaneous coronary intervention (PCI) market statistics, including robot-assisted percutaneous coronary intervention (PCI) industry global market size, regional shares, competitors with a robot-assisted percutaneous coronary intervention (PCI) market share, detailed robot-assisted percutaneous coronary intervention (PCI) market segments, market trends and opportunities, and any further data you may need to thrive in the robot-assisted percutaneous coronary intervention (PCI) industry. The robot-assisted percutaneous coronary intervention (PCI) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The robot-assisted percutaneous coronary intervention (PCI) market consists of revenues earned by entities by providing services such as robotic catheter navigation, remote-controlled stent placement, real-time imaging integration, and procedural planning support. The market value includes the value of related goods sold by the service provider or included within the service offering. The robot-assisted percutaneous coronary intervention (PCI) market also includes sales of radiation shielding accessories, robotic arm components, monitoring and display units, integration interfaces, and sterile disposable kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.